Table 1. Patient characteristics.

Pat	Dose level	Age	Sex	# Pretreatments	Type of pretreatment	Gene, exon	Primary mutation	ECOG	PET-response	RECIST	Days on study treatment
101	20	34	m	11	IM, SU, other	KIT exon 11, Exon 17	Del E554-V559; D820Y	0	mPD	PD	25
102	20	41	m	5	IM, SU, Nilo, Sora, other	PDGFR Exon 12	Del V559-P573; D820G	0	mPR	SD	116
103	30	60	m	4	IM, SU, Dasa, Nilo	PDGFR Exon 18	D842V	0	mSD	PD	12
104	30	38	w	5	IM, SU, Nilo, Sora, other	KIT exon 9	duplication A502 and Y503; Y823D		mPD	SD	26
106	20 Extension	75	w	4	IM, SU, Nilo, Sora	—	NA	1	mSD	SD	35
107	20 Extension	38	m	4	IM, SU, Nilo, other	KIT intron 10/exon 11	K550–558dela	0	mPD	—	18
108	20 Extension	55	m	5	IM, SU, other	KIT, Exon 11	K558-V559insP	0	mSD	SD
201	20	56	m	3	IM, SU, other	KIT, Exon 13	K642E	0	mSD	SD	74
202	30	54	w	4	IM, SU, other	c-KIT Exon 11	Del K558	1	mSD	SD	65
203	30	74	w	5	IM, SU, Sora, other	—	Exon 11 wt, other exons not analysed	1	—	PD	86
204	20	63	w	8	IM, SU,Nilo, Sora, other	KIT, Exon 9	Duplication A502 and Y503	1	mSD	SD	51
205	20	69	m	10	IM, SU, Nilo, Sora, other	KIT, Exon 11	Y553-K558delinsW	1	mSD	SD	72

Abbreviations: IM=imatinib; mPD=metabolic progressive disease; mPR=metabolic partial response; mSD=metabolic stable disease; NA=not applicable; Nilo=nilotinib; Sora=Sorafenib; SU=sunitinib.

^aMutational analysis kindly provided by Professor Stephan Dirnhofer, Basel.